ScaleReady Collaborates to Support Moonlight Bio with G-Rex Grant for Innovative Cancer Therapies
In a significant stride towards advancing cancer treatment, ScaleReady has announced the provision of a G-Rex® Grant to Moonlight Bio, a company pioneering CAR T cell therapy aimed at solid tumors. This collaboration includes notable partners such as Wilson Wolf Manufacturing and Bio-Techne Corporation. The grant, part of ScaleReady's commitment to promoting the field of cell and gene-modified therapies (CGT), could greatly expedite Moonlight Bio's process development and IND-enabling studies for their lead CAR T asset.
The funding will enable Moonlight Bio to leverage ScaleReady’s extensive expertise and a manufacturing platform that is both cost-effective and scalable. Dr. Jordan Jarjour, Chief Scientific Officer at Moonlight Bio, expressed gratitude for this opportunity, emphasizing how it will streamline their path to clinic viability for CAR T therapies, which aim to create more efficient therapies that could catalyze significant breakthroughs in treating solid tumors. He pointed out that this grant not only saves valuable time but also reduces operational costs for biotech companies.
John Wilson, CEO of Wilson Wolf Manufacturing, echoed this sentiment, highlighting the importance of G-Rex and ScaleReady's role in preserving resources that are crucial for success in the cell therapy sector. The G-Rex manufacturing platform has already proven its efficacy in over 800 organizations worldwide and contributes to nearly half of all CGT clinical trials with effective production processes.
The technology that underpin’s Moonlight Bio's therapies draws from groundbreaking research published in Nature by Dr. Kole Roybal and Dr. Jaehyuk Choi. Their research delineates a method to boost T cell therapies through the utilization of naturally occurring mutations within T cell malignancies. By screening various mutations, they aim to discover innovative approaches to enhance the efficacy of T cell therapies based on cancer evolution. This promising methodology underscores Moonlight Bio's commitment to creating robust treatments for patients battling cancer, which is often inadequately addressed by existing therapies.
The G-Rex Grant will provide Moonlight Bio with access to a commercially viable CAR T manufacturing platform and can also be applied toward essential validation runs that support their research endeavors. Furthermore, they will benefit from Bio-Techne's affordable closed-system reagent solutions and GMP Cytokines designed to simplify cytokine delivery, alongside a complimentary analysis of their master manufacturing batch records by CellReady – a specialized CDMO focused on G-Rex processes.
ScaleReady’s G-Rex Grant Program itself is a $20 million initiative earmarked to enhance the development and manufacturing of CGT. Each award can reach up to $300,000, supporting extensive access to a consortium of G-Rex Grant Partners. These partners contribute their advanced tools, technologies, and invaluable knowledge in the realms of regulatory affairs, quality, and commercial operations, reinforcing the prospects of successful clinical trials.
Moonlight Bio, situated in Seattle, WA, is carving a niche for itself within the biotech landscape, striving to develop T cell therapies that hold greater potency against solid tumors, thus promising new treatment avenues for patients in dire need. The collaboration with ScaleReady marks a landmark opportunity for Moonlight Bio to propel their research forward, underpinning their ethos of delivering meaningful solutions in oncology.
For more details about ScaleReady and the G-Rex Grant Program, interested parties can contact them directly through their communications channels. This ambitious endeavor by ScaleReady, in concert with its partners, represents a vital step in reshaping the future of cancer treatment through innovative therapies and efficient manufacturing processes.
The funding will enable Moonlight Bio to leverage ScaleReady’s extensive expertise and a manufacturing platform that is both cost-effective and scalable. Dr. Jordan Jarjour, Chief Scientific Officer at Moonlight Bio, expressed gratitude for this opportunity, emphasizing how it will streamline their path to clinic viability for CAR T therapies, which aim to create more efficient therapies that could catalyze significant breakthroughs in treating solid tumors. He pointed out that this grant not only saves valuable time but also reduces operational costs for biotech companies.
John Wilson, CEO of Wilson Wolf Manufacturing, echoed this sentiment, highlighting the importance of G-Rex and ScaleReady's role in preserving resources that are crucial for success in the cell therapy sector. The G-Rex manufacturing platform has already proven its efficacy in over 800 organizations worldwide and contributes to nearly half of all CGT clinical trials with effective production processes.
The technology that underpin’s Moonlight Bio's therapies draws from groundbreaking research published in Nature by Dr. Kole Roybal and Dr. Jaehyuk Choi. Their research delineates a method to boost T cell therapies through the utilization of naturally occurring mutations within T cell malignancies. By screening various mutations, they aim to discover innovative approaches to enhance the efficacy of T cell therapies based on cancer evolution. This promising methodology underscores Moonlight Bio's commitment to creating robust treatments for patients battling cancer, which is often inadequately addressed by existing therapies.
The G-Rex Grant will provide Moonlight Bio with access to a commercially viable CAR T manufacturing platform and can also be applied toward essential validation runs that support their research endeavors. Furthermore, they will benefit from Bio-Techne's affordable closed-system reagent solutions and GMP Cytokines designed to simplify cytokine delivery, alongside a complimentary analysis of their master manufacturing batch records by CellReady – a specialized CDMO focused on G-Rex processes.
ScaleReady’s G-Rex Grant Program itself is a $20 million initiative earmarked to enhance the development and manufacturing of CGT. Each award can reach up to $300,000, supporting extensive access to a consortium of G-Rex Grant Partners. These partners contribute their advanced tools, technologies, and invaluable knowledge in the realms of regulatory affairs, quality, and commercial operations, reinforcing the prospects of successful clinical trials.
Moonlight Bio, situated in Seattle, WA, is carving a niche for itself within the biotech landscape, striving to develop T cell therapies that hold greater potency against solid tumors, thus promising new treatment avenues for patients in dire need. The collaboration with ScaleReady marks a landmark opportunity for Moonlight Bio to propel their research forward, underpinning their ethos of delivering meaningful solutions in oncology.
For more details about ScaleReady and the G-Rex Grant Program, interested parties can contact them directly through their communications channels. This ambitious endeavor by ScaleReady, in concert with its partners, represents a vital step in reshaping the future of cancer treatment through innovative therapies and efficient manufacturing processes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.